Companies › Mirador Therapeutics
3 active drug programs in 5 registered trials: 3 Phase 1, 2 Phase 2; Immunology, Other; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Adecatumumab (MT-201) Epithelial cell adhesion molecule inhibitor | EPCAM | Phase 2 | Inflammatory Bowel Disease (IBD); Healthy Volunteer | Nov 2026 |
| MT-501 | – | Phase 2 | Inflammatory Bowel Disease (IBD) | Apr 2027 |
| MT-251 | – | Phase 1 | Healthy Volunteers | Mar 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07776782 | Adecatumumab (MT-201) | Phase 1 | Healthy Volunteer | Other | Nov 2026 |
| NCT07219368 | Adecatumumab (MT-201) | Phase 1 | Healthy Volunteer | Other | Nov 2026 |
| NCT07423299 | MT-251 | Phase 1 | Healthy Volunteers | Other | Mar 2027 |
| NCT07113522 | Adecatumumab (MT-201) | Phase 2 | Inflammatory Bowel Disease (IBD) | Immunology | Apr 2027 |
| NCT07113522 | MT-501 | Phase 2 | Inflammatory Bowel Disease (IBD) | Immunology | Apr 2027 |
Accro Bioscience (Suzhou) Astria Therapeutics Clarent Biopharma Oruka Therapeutics Shanghai Argo Biopharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.